Baiyu Pharm

A Global Fully Integrated Innovative Pharmaceutical Group


Corporate Presentation Contents

- 1. Corporate Overview
- 2、Product Research & Development
- 3. Manufacturing and Supply
- 4. Domestic Marketing & Distribution
- **5**、International Business Development




Corporate Overview

A Glance At Baiyu (2019)




Corporate Overview-Development History





Corporate Overview

Annual Operating Revenue Exceeds RMB 1.2 Billion in 2019 with Annual Growth > 20%;






Product R&D

Driven by Innovation to Satisfy Unmet Medical Needs

Product R&D-Platform

International Standard of R&D Platform Consisting of Two Research Division (Innovative & Generic)


2019 R&D Expenditure Investment exceeds 90 million RMB Yuan, accounting for 8% of the annual operating revenue.





Product R&D Pipeline

Product Pipeline




Product R&D-NCE Pipeline

DD-2001	DD-1002	Summary:
Indication: Hemiplegia Best-in-class	Neuroprotection Best-in-class	Category: New chemical entity
		Designation: First-in-class
DD-2003 Anti-inflammation First-in-class	DD-1004 Inhibiting tumor proliferation First-in-class	Best-in-class/Me-Better Therapeutic Area:
DD-2005 Cardiovascular protection	DD-2006 Inhibiting tumor mutation	CVS, Tumor, Inflammation Immunology
First-in-class	Best-in-class	Category:
DD-1008 Central nervous protection First-in-class Best-in-class	DD-2113 Antiviral Best-in-class	Antibody (Monoclonal antibody, Double-antibody, New antibody); Designation: First-in-class;
		Therapeutic Area: CVS, Inflammation, Immunology;



Product R&D-IP& Patent

Well Established IP Protection, Patent Designation Review





Product R&D-Pipeline

List of Commercialized FDF Product Portfolios

Baiyu focuses on **cardiovascular** and **cerebrovascular** diseases with a variety of product portfolios in the therapeutic areas of cardiovascular, neuropsychiatric, digestive system, anti-infection, Pain Management, tumor and other areas.





Highlight Product: GINKGOLIDE ®: Global leader in Ginkgo Herbal Drugs




Injection Extracted from Herbal

- Advanced technology lead global ginkgo drugs from the extraction mixture into the molecular-based era;
- In 2019, the Chinese National Administration Law classified GINKOLIDE as Class 1.1 of Innovative Traditional Chinese Medicines;
- The first innovative anti-PFA drug launched globally;
- Accumulated sales volume has reached 3.6 billion RMB Yuan in last 7 years;
- Global Market under evaluation and promotion in Key Regions.




Highlight Product: GINKGOLIDE [®]: New Standardized Ginkgo with better stability

Different from the compatibility theory of traditional Chinese medicine, Baiyu Ginkgolide breaks through the problems of unclear ingredients, unclear mechanism and uncertain effect of traditional Chinese medicine; Optimized Product Impurity Profile compared with EGb761®, Cage-like molecular structure acts at the PAF target.






Global leading extracting technology to be the first molecular-level GINKGOLIDE®




Pathways for R&D of plant-based Herbal Drugs





- Dr. Schwabe, a plant medicine expert with 150 years of history, has successively launched the First to Fourth generation of Herbal preparations containing ginkgo biloba extract;
- Baiyu launched the Fifth generation of Ginkgo biloba extract preparation with technical breakthrough and lead the development of modern Chinese Herbal Drugs.



GINKGOLIDE® : Using breakthrough Formulation Technology




Published in Angew Chem Int Ed Engl in 2004: Bilobalide and ginkgolide are the core components of Ginkgo biloba extract (EGB761), which are effective ingredients that regulate the function of the nervous system.

> Dr. Zhongxi Xianger (The discoverer of the

ginkgolide structure))

In 2008, the U.S. Pharmacopeia raised the standard for ginkgolide content in ginkgo biloba extract from 6 percent to 12 percent.





Characteristics of ginkgolide: Cage-like molecular structure

- A fat-soluble ingredient can pass through the blood-brain barrier

- Very low content
- Insoluble in water, hardly soluble in many organic solvents
- The ring structure is easy to be destroyed in the extraction process
 - Cannot be synthesized artificially

Ginkgolide is the most important effective component of Ginkgo biloba leaves, and it cannot be synthesized artificially because of "cage-ike molecular structure". Modern extraction, separation, purification and preparation technology are the key to solve the problems of ginkgolide, such as insoluble raw material, unstable chemical structure and unstable preparation.


Technology on extraction

Overcomes the extremely low content of ginkgolide in leaves, and the extraction purity is as high as 99%

Technology on preparation

Solves the problems of insoluble raw materials, unstable structure in organic solvents, easy destruction of cyclic structure and impurities.

GINKGOLIDE® : Proven to be effective and Safe through Clinical Evidence-Based Record



Product R&D-Ginkgolide Pallet

GINKGOLIDE Pallet® : Promising Alternative Therapy Against Anti-Aspirin Asian

•



- Innovative Target with New Mechanism: The global unique medicines capable of combining Neuroprotection and antiplatelet aggregation of neurovascular units double mechanism.
 - **Evidence-Based:** Proved to be effective and safe with more than 20,000 subjects clinical evidence data for treatment of cerebral apoplexy and coronary heart disease;
 - **Patented Tech.:** 36 Steps of patented technology to control and ensure the consistency of molecular-level quality;
- **Marketing Value**: Plan to submit as Herbal Drugs in EU/US with potential market value to be US 1 billion.
- Clinical Stage: Stage II in P.R. China.



Operates in Compliance with Strictly cGMP Regulation

Integrated Manufacturing and Supply Chain

- Four Ginkgo Biloba Leaves planting bases;
- One API Manufacturing Site (Sichuan Yujian);
- Three FDF Manufacturing Sites;

(Wenjiang/Ginkgolide and Medical City Site)

• One Medical Devices Factory (Mask Medical Supply);



Chengdu Baiyu Mask Supply Co., Ltd. 4 adult face masks line: 500,000 pieces per day; 1 children's mask line: 120,000 pieces per day; 13 KN95 Standard masks 480,000 pieces per day;



Sichuan Yujian Pharm. Co., Ltd.

- Established in 2017 covering a area of 130k square meters;
- Operates in compliance with US/EU cGMP.

Medical City Site

- Established in 2019 covering area of 105k square meters for FDF Manufacturing;
- Operates in compliance with US/EU cGMP;

Baiyu Ginkgolide Pharma Co., Ltd.

- Established in 2013 covering area of 53k square meters for FDF Manufacturing;
- Operates in compliance with US/EU cGMP

Wenjiang Site

- Established in 2005 covering area of 20k square meters for FDF Manufacturing;
- Operates in compliance with China GMP.



API

FDF

Start of Art Manufacturing Facility



Intelligent Informalized System

ERP+OA System: Enable traceable online management.

Real Time Remote Recording and Monitoring

All data automatically submitted and recorded in SCADA server to enable real-time recording and monitoring of process.

Process Automation

DCS System, Automatically and precisely control CPP;

Compact Warehousing

Tridimensional warehouse saving 90% space through

WCS+WMS: Standardized EHS

Three-stage condensation + distillation plus 'Activated Carbon fiber adsorption and desorption, and the real-time online monitoring of end exhaust gas.



Medical City Site Introduction

Design Capacity: Capable of processing 4.5 tons of Ginkgo biloba leaves per day, with 7.5 tons output of ginkgolide crystallized raw materials per year;

Design Objective: one of the most automatic extraction workshops in China;

Design Concept:

- High level of automation: Rockwell DCS controller enable precise automatic control of materials charging and processing
 of plant extraction through more than 6000 I / O control points, 3500 sets of automatic valves and more than 1000 sensors
 and meters.
- In-Process Quality Control: High level of quality in-process control and automagical recording system to enable permanent traceability of manufacturing CPP and other parameters covering all quality control and quality assurance activities;
- **Improved Efficiency:** the system enables the using 72 column through intelligent scheduling resulting in the six times output by saving 90% of labor resources.







Baiyu Ginkgolide Site Introduction



Ginkgolide Production Line:

Advanced Equipment Makes Advanced Production Line.

Select advanced aseptic process using real-time monitoring equipment:

Dynamic monitoring of the whole process and continuous, effective, safe and reliable clean production environment

Global leading washing, drying and filling automatic production line (German Made):

Capable of handling small-volume injection and lyophilized powder injection with 400 vials /min.

Automatic dispensing system:

Automatic recording, adjustment and feedback information plus automatic cleaning sterilization.



Target to be the global leading Mask Supplier

Capacity:

Medical Standard Grade 99 melt blown cloth production line, with an annual output of 1000 tons

Annual production output of medical surgical masks: 300 million pieces and medical protective masks are 300 million pieces with 3,000 square meters clean Room workshop and 40 automatic mask production lines

Certification:

EU CE Certified, Germany EUA Certified, Ministry of Commerce white Clean list;

Currently under qualification process for US Niosh 95, Japan PMDA and China Medical Devices; **OEM:** Under qualification process for OEM Supplier of Honeywell.

Melt blown Cloth Workshop









Clean Room(ISO 8/100K) for Mask Workshop







Domestic Marketing & Distribution

Baiyu establishes a effective and broad nation-wide drug product Marketing & Distribution System to cover entire China Hospital and Retail Drug Market through working flexibly with our sub-contractor /Sales agents and partners.



International Business Development

To Build A Global Marketing Network

International Business Development

Strategy & Executive Business Plan

API Keep filing API products with continuous marketing

Intern. BD & License Identify products to license-in to fill pipeline and develop both domestically and globally

CDMO/CMO

Leverage Baiyu expertise and technology to serve global customer;

Ginkgolide Develop Baiyu Ginkgolide FDF internationally to global patients



R

FDF

Mask & PPEs Build Baiyu Mask Brand to promote in global market

High Quality Products by filing with global marketing authorities



Strategic Cooperation Identify with global partner for Strategic Cooperation







International Business Development

Build International Operational System

International Management

- Introduce top international and overseas background talents to Baiyu.
- The current team used to work in well-known companies such as SUGEN, Hawaii Biotech, GlaxoSmithKline, Sanofi, Pfizer, Novartis, Bayer, Dr. Reddy'S, Deloitte, PWC, IMS Capital, etc.

Intenational R&D

- License-in: License-in from EU top 5 countries, expand the product pipeline.
- NDA: To submit the European clinical trial application of global innovative drug-ginkgolide injection.
- International R & D institutions: Invest and acquire international advanced technology research institute, and build overseas research branches around Chengdu Central Research Institute.

International Marketing Manufacturing System

Continue to promote the establishment of overseas centers to develop international sales channel and to conduct:

- Ginkgo Product Marketing
- Generic Marketing
- API Marketing
- Inovatinve Drug Marketing
- PPEs Marketing

Continue to promote Baiyu Ginkgolide factory, Yujian factory, Wenjiang Medical City factory to pass EU certification and more international certifications, also considering high-quality matching overseas investment and acquisition opportunities.



Contact US

International Business Department

Address: No.343 Hezuo Road, West Hi-Tech Zone, 611731, Chengdu, Sichuan, China.

Tel: +86-28 83379750, ext 8011

Email: sales@baiyu.cn

